Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis

[1]  G. Molenberghs,et al.  Validation of surrogate end points in multiple randomized clinical trials with failure time end points , 2001 .

[2]  G. Molenberghs,et al.  The validation of surrogate endpoints in meta-analyses of randomized experiments. , 2000, Biostatistics.

[3]  G. Molenberghs,et al.  Criteria for the validation of surrogate endpoints in randomized experiments. , 1998, Biometrics.

[4]  D. Cocchetto,et al.  Faster Access to Drugs for Serious or Life-Threatening Illnesses Through use of the Accelerated Approval Regulation in the United States , 1998 .

[5]  M. Buyse,et al.  Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  V De Gruttola,et al.  Estimating the proportion of treatment effect explained by a surrogate marker. , 1997, Statistics in medicine.

[7]  H. Wieand,et al.  Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M Buyse,et al.  On the relationship between response to treatment and survival time. , 1996, Statistics in medicine.

[9]  V. Sondak,et al.  Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. , 1996, Journal of the National Cancer Institute.

[10]  J. P. Pignon,et al.  Efficacy of adjuvant fluorouracil and folinic acid in colon cancer International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators , 1995, The Lancet.

[11]  H. Kantarjian,et al.  Prolonged Survival in Chronic Myelogenous Leukemia after Cytogenetic Response to Interferon- Therapy , 1995, Annals of Internal Medicine.

[12]  L. Påhlman,et al.  The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. , 1994, British Journal of Cancer.

[13]  M S Pepe,et al.  Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research. , 1994, Statistics in medicine.

[14]  M. Buyse,et al.  Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer , 1994 .

[15]  H. Rockette,et al.  The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[17]  J. Armitage,et al.  Treatment of non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[18]  P. Piedbois.  Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  B. Graubard,et al.  Statistical validation of intermediate endpoints for chronic diseases. , 1992, Statistics in medicine.

[20]  J R Anderson,et al.  Analysis of survival by tumor response. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Temple,et al.  Food and Drug Administration requirements for approval of new anticancer drugs. , 1985, Cancer treatment reports.

[22]  M. Shapiro,et al.  Reporting results from chemotherapy trials. Does response make a difference in patient survival? , 1984, JAMA.

[23]  J. Hokanson,et al.  Comparing survival of responders and nonresponders after treatment: a potential source of confusion in interpreting cancer clinical trials. , 1983, Controlled clinical trials.

[24]  P. Lavin,et al.  Survival and response to chemotherapy for advanced colorectal adenocarcinoma. An eastern cooperative oncology group report , 1980, Cancer.